Standout Papers

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advance... 2018 2026 2020 2023 320
  1. Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors (2018)
    Julius Strauss, Christopher R. Heery et al. Clinical Cancer Research

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 65 standout
Sub-graph 1 of 20

Citing Papers

Probiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 StandoutNature
Refining the impact of genetic evidence on clinical success
2024 StandoutNature
4 intermediate papers

Works of Christoph Helwig being referenced

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
2018 Standout
Preliminary results from a phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors.
2017

Author Peers

Author Last Decade Papers Cites
Christoph Helwig 1144 272 211 450 328 52 1.4k
Raid Aljumaily 992 244 397 267 272 80 1.3k
Roberto Patuzzo 936 109 101 430 383 56 1.2k
Luciane T. Kagohara 560 194 74 234 487 40 1.1k
Meagan Montesion 741 314 115 191 546 46 1.4k
Suroosh S. Marzban 890 170 62 224 226 25 1.0k
Lisa M. Cordes 1140 398 260 509 293 100 1.5k
Aaron Lisberg 1367 815 106 262 177 69 1.6k
Boel Ragnarsson-Olding 1094 105 231 324 402 30 1.4k
Rodrigo Ramella Munhoz 800 271 81 387 307 54 1.1k
Lynn T. Dengel 666 66 131 480 168 35 1.0k

All Works

Loading papers...

Rankless by CCL
2026